Ignite Creation Date:
2025-12-26 @ 11:14 AM
Ignite Modification Date:
2026-02-21 @ 11:18 PM
Study NCT ID:
NCT03302728
Status:
COMPLETED
Last Update Posted:
2022-05-19
First Post:
2017-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma
Sponsor:
Peter MacCallum Cancer Centre, Australia
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
17/34
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None